Master Protocol for Crizotinib Continuation Sub-Studies

You may be able to join if

• Any participant who is receiving crizotinib and deriving clinical benefit (as determined by the investigator) in a Pfizer-sponsored Crizotinib Parent Study.
• Participants must agree to follow the reproductive criteria as outlined in Appendix 4 (Section 10.4.1 for males and Section 10.4.2 for females).
• No ongoing NCI CTCAE Grade ≥3 or intolerable Grade 2 Aes considered to be related to crizotinib treatment, except for those laboratory eligibility criteria described in Inclusion #4.
• Adequate organ function as defined by the following criteria: Adults Participants (≥18 years): • Hepatic function: Serum AST and serum ALT ≤3 × ULN, or AST and ALT ≤5 × ULN if liver function abnormalities were due to underlying malignancy; total serum bilirubin ≤1.5 × ULN (except participants with documented Gilbert's syndrome); • Bone marrow function: ANC ≥1000/μL, platelets ≥50,000/μL; hemoglobin ≥8.0 g/dL; • Stable renal function for at least 14 days. Pediatric Participants (<18 years): • Hepatic function defined as ≤3 × ULN for ALT and AST and ≤1.5 ×ULN for bilirubin, or ≤5 × ULN for ALT and AST and ≤1.5 × ULN for bilirubin in case of liver involvement by metastases; • Adequate hematological function: • ANC ≥750/μL and platelets ≥75,000/μL for participants without bone marrow involvement; • Participants with bone marrow involvement will be allowed to enter with ANC ≥500/μL and platelets ≥50,000/μL; • Stable renal function for at least 14 days.